Soligenix, Inc. (SNGX)


OTC BB - OTC BB Delayed Price. Currency in USD
0.59-0.00 (-0.42%)
As of 10:41 AM EDT. Market open.
People also watch:
FCSCSYNTPIVOGENAPHB
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open0.59
Prev Close0.59
Bid0.00 x
Ask0.00 x
Day's Range0.58 - 0.59
52wk Range0.44 - 1.49
1y Target EstN/A
Market Cap19.73M
P/E Ratio (ttm)-9.48
Beta-0.05
Volume29,586
Avg Vol (3m)95,029
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Zacks Small Cap Research6 days ago

    SNGX: Orphan Drug Designation Granted for Dusquetide for Treatment of Macrophage Activation Syndrome

    On Aug. 18, 2016, Soligenix (SNGX) announced that the FDA has granted orphan drug designation to dusquetide for treatment of macrophage activation syndrome (MAS).  Dusquetide has previously received orphan drug designation for the treatment of acute radiation syndrome (ARS). In addition to providing a seven-year term of market exclusivity upon final FDA approval, orphan drug designation also positions Soligenix to be able to leverage a wide range of financial and regulatory benefits, including government grants for conducting clinical trials, waiver of expensive FDA user fees for the potential submission of a New Drug Application, and certain tax credits.

  • PR Newswire6 days ago

    FDA Grants Soligenix Orphan Drug Designation for Dusquetide for Treatment of Macrophage Activation Syndrome

    PRINCETON, N.J., Aug. 18, 2016 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat ...

  • Soligenix, Inc. :SNGX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 16, 2016
    Capital Cube8 days ago

    Soligenix, Inc. :SNGX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 16, 2016

    Categories: Yahoo Finance Get free summary analysis Soligenix, Inc. reports financial results for the quarter ended June 30, 2016. We analyze the earnings along side the following peers of Soligenix, Inc. – Emergent BioSolutions Inc., Johnson & Johnson, Pfizer Inc., Teva Pharmaceutical Industries Limited Sponsored ADR and Athersys, Inc. (EBS-US, JNJ-US, PFE-US, TEVA-US and ATHX-US) that have also ... Read more (Read more...)